Compare MTEX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEX | ENLV |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 26.6M |
| IPO Year | 1999 | 1995 |
| Metric | MTEX | ENLV |
|---|---|---|
| Price | $8.65 | $0.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 3.9K | ★ 11.5M |
| Earning Date | 11-12-2025 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,411,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.50 | $0.83 |
| 52 Week High | $16.49 | $2.10 |
| Indicator | MTEX | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 39.05 | 43.10 |
| Support Level | $9.01 | $0.89 |
| Resistance Level | $9.68 | $1.25 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 0.00 | 5.26 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.